Department of Surgery, Cardiothoracic Surgery, Saint Louis University School of Medicine, 3635 Vista Avenue, 8th Floor Des Loges Towers, St Louis, MO 63110, USA.
Cardiol Clin. 2010 May;28(2):213-20. doi: 10.1016/j.ccl.2010.01.018.
The fundamental requirements for a meaningful biomarker have not been met in the prediction of the aneurysm trait, the progression of the aneurysm disease state, or the prevention of catastrophic aortic complications. Aortic aneurysm is a worthy opponent on all fronts, and clinicians should continue actively to evaluate all potential diagnostic and therapeutic adjuncts with high levels of scientific scrutiny and rigor, so that the understanding and management of this disease process evolves in a complementary, rather than duplicative, manner. In the meantime, proteomics, genomics, and metabolomics continue to represent a muse of sorts in scientific circles, but clinicians are responsible for verifying the relevance and meaningful application of its postulates as they apply to individual patients within the context of efficient and effective global health care delivery.
在预测动脉瘤特征、动脉瘤疾病状态的进展或预防灾难性主动脉并发症方面，有意义的生物标志物的基本要求尚未得到满足。主动脉瘤在各个方面都是一个值得关注的对手，临床医生应继续积极评估所有潜在的诊断和治疗辅助手段，以高度的科学审查和严谨性进行评估，以便以互补而非重复的方式来发展对这种疾病过程的理解和管理。与此同时，蛋白质组学、基因组学和代谢组学继续在科学界中具有一定的吸引力，但临床医生有责任验证其假设在个体患者中的相关性和实际应用，同时在高效和有效的全球医疗保健提供的背景下。
